Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Atomo Diagnostics Ltd. ( (AU:AT1) ).
Atomo Diagnostics Limited successfully placed the shortfall of $727,612.50 from its Share Purchase Plan to sophisticated investors, raising a total of $260,000 through the issuance of 14,054,054 shares. The funds will support the company’s general working capital and ongoing business objectives, strengthening its operational activities. The placement was managed by Bay Financial Pty Ltd and GBA Capital Pty Ltd, with a 6% fee on the funds placed.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Limited is an Australian-headquartered medical device company that supplies unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. The company focuses on simplifying testing procedures, enhancing usability, and improving reliability for rapid point-of-care and at-home testing applications. Atomo has commercialized products internationally and has supply agreements for testing applications targeting infectious diseases such as HIV, Active Syphilis, viral vs bacterial differentiation, and early pregnancy detection.
Average Trading Volume: 988,590
Technical Sentiment Signal: Hold
Current Market Cap: A$15.42M
Find detailed analytics on AT1 stock on TipRanks’ Stock Analysis page.